Adverum Biotechnologies, Editas Medicine extend research collaboration.
Adverum Biotechnologies (ADVM) announced an extension of its collaboration agreement with Editas Medicine (EDIT). The companies established this collaboration to explore the delivery of genome editing medicines to treat up to five inherited retinal diseases. "Our collaboration with Editas is focused on utilizing our next-generation adeno-associated viral vectors to deliver Editas' CRISPR-based genome editing technologies to develop novel therapies for debilitating eye diseases," said Amber Salzman, Ph.D., President and Chief Executive Officer, Adverum Biotechnologies. "Extending our collaboration validates the important work underway to use our next-generation vectors." "This collaborative work brings together our best-in-class genome editing platform and Adverum's industry-leading vectors with a goal of developing new medicines for patients with retinal diseases," said Katrine Bosley, Chief Executive Officer, Editas Medicine. "Adverum has a distinctive technology and significant ophthalmology experience. Expanding our relationship is reflective of our strategy to continue investing in our platform in a highly selective manner." Under the terms of the extended agreement, Adverum and Editas are extending the research period through third quarter of 2018. Editas maintains a series of options exercisable between now and August 2020.
|Printer friendly Cite/link Email Feedback|
|Date:||Jan 25, 2018|
|Previous Article:||Alnylam receives EMA accpetance of MAA for patisiran.|
|Next Article:||Intel sees FY18 EPS $3.55 plus or minus 5%, consensus $3.27.|